Skip to content

Study · Non-randomized trial · 1995

4 results

Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism.

Heiner JS, Greendale GA, Kawakami AK, Lapolt PS, Fisher M, Young D, Judd HL

The Journal of clinical endocrinology and metabolism1 Dec 1995Cited by 32 (Europe PMC)

PMID8530574 (opens in a new tab)DOI10.1210/jcem.80.12.8530574 (opens in a new tab)PepBankPUB-08530574
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with hirsutism, nafarelin alone significantly reduced total testosterone (P = 0.01).

    In plain wordsIn women with hirsutism, nafarelin alone reduced total testosterone from baseline.

    Peptide
    Nafarelin
    Outcome
    DecreaseTotal testosterone
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms twice daily · intranasal spray · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    With treatment, significant reductions (P = 0.01) in total T were seen with combination and NAF only therapy.
    1 context sentence
    Summary · context
    We enrolled 64 women in a 24-week blinded randomized controlled trial to compare placebo, nafarelin (NAF; 400 micrograms, intranasal spray, twice daily), norethindrone (1 mg), and ethinyl estradiol (NOR 1/35; 0.035 mg, daily, for 3 of 4 weeks), or combined use of NAF and NOR 1/35 for 24 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with hirsutism, nafarelin alone did not significantly decrease hair shaft diameter.

    In plain wordsIn women with hirsutism, nafarelin alone did not significantly reduce hair thickness.

    Peptide
    Nafarelin
    Outcome
    No significant changeHair shaft diameter
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    400 micrograms twice daily · intranasal spray · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There was a significant decrease in hair shaft diameter after combination therapy (P < 0.05) that was not seen with either agent alone.
    1 context sentence
    Summary · context
    We enrolled 64 women in a 24-week blinded randomized controlled trial to compare placebo, nafarelin (NAF; 400 micrograms, intranasal spray, twice daily), norethindrone (1 mg), and ethinyl estradiol (NOR 1/35; 0.035 mg, daily, for 3 of 4 weeks), or combined use of NAF and NOR 1/35 for 24 weeks.
  3. 03HumanNon-randomized trialSafety outcome

    In women with hirsutism, hot flashes occurred with nafarelin alone.

    In plain wordsIn women with hirsutism, hot flashes occurred with nafarelin alone.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedHot flashes
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    400 micrograms twice daily · intranasal spray · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Combination therapy also prevented the hot flashes and bone loss that occurred with agonist alone.
    1 context sentence
    Summary · context
    We enrolled 64 women in a 24-week blinded randomized controlled trial to compare placebo, nafarelin (NAF; 400 micrograms, intranasal spray, twice daily), norethindrone (1 mg), and ethinyl estradiol (NOR 1/35; 0.035 mg, daily, for 3 of 4 weeks), or combined use of NAF and NOR 1/35 for 24 weeks.
  4. 04HumanNon-randomized trialSafety outcome

    In women with hirsutism, bone loss occurred with nafarelin alone.

    In plain wordsIn women with hirsutism, bone loss occurred with nafarelin alone.

    Peptide
    Nafarelin
    Outcome
    DecreaseBone mineral density
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 micrograms twice daily · intranasal spray · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Combination therapy also prevented the hot flashes and bone loss that occurred with agonist alone.
    1 context sentence
    Summary · context
    We enrolled 64 women in a 24-week blinded randomized controlled trial to compare placebo, nafarelin (NAF; 400 micrograms, intranasal spray, twice daily), norethindrone (1 mg), and ethinyl estradiol (NOR 1/35; 0.035 mg, daily, for 3 of 4 weeks), or combined use of NAF and NOR 1/35 for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.